Bevacizumab: a new way of doing business. Part 2

Affiliations

¹ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, South Lab and Path Block, Mailpoint 806, Level D, University Hospital Southampton, Southampton SO16 6YD, Southampton, UK. a.j.lotery@soton.ac.uk.
² Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, NHS Foundation Trust, Mindelsohn Way Edgbaston, Birmingham, B15 2TH, UK.

Editorial

Andrew J Lotery et al. Eye (Lond). 2019 Apr.

. 2019 Apr;33(4):519-520.

doi: 10.1038/s41433-018-0281-2. Epub 2018 Nov 27.

¹ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, South Lab and Path Block, Mailpoint 806, Level D, University Hospital Southampton, Southampton SO16 6YD, Southampton, UK. a.j.lotery@soton.ac.uk.
² Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, NHS Foundation Trust, Mindelsohn Way Edgbaston, Birmingham, B15 2TH, UK.

No abstract available

Conflict of interest statement

The authors declare that they have no conflict of interest.

1. Canning C, Lotery A. Bevacizumab: a new way of doing business? Eye. 2007;21(6):891–891. doi: 10.1038/sj.eye.6702777. - DOI - PubMed
1. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–67. doi: 10.1016/S0140-6736(13)61501-9. - DOI - PubMed
1. Lotery A, MacEwen C. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? BMJ. 2014;349:g6887. doi: 10.1136/bmj.g6887. - DOI - PubMed
1. Shalaby AK, Lewis K, Bush K, Meredith PR, Di Simplicio S, Lockwood AJ. Licence to save: a UK survey of anti-VEGF use for the eye in 2015. Eye (Lond) 2016;30(11):1404–6. doi: 10.1038/eye.2016.154. - DOI - PMC - PubMed
1. Foot B, MacEwen C. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome. Eye (Lond) 2017;31(5):771–5. doi: 10.1038/eye.2017.1. - DOI - PMC - PubMed